These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36967437)

  • 1. Methotrexate in generalized myasthenia gravis: a systematic review.
    Prado MB; Adiao KJB
    Acta Neurol Belg; 2023 Oct; 123(5):1679-1691. PubMed ID: 36967437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis.
    Heckmann JM; Rawoot A; Bateman K; Renison R; Badri M
    BMC Neurol; 2011 Aug; 11():97. PubMed ID: 21819556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methotrexate as a Steroid-Sparing Agent in Myasthenia Gravis: A Preliminary Retrospective Study.
    Rodolico C; Bonanno C; Brizzi T; Nicocia G; Trimarchi G; Lupica A; Pugliese A; Musumeci O; Toscano A
    J Clin Neuromuscul Dis; 2021 Dec; 23(2):61-65. PubMed ID: 34808648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis.
    Pasnoor M; He J; Herbelin L; Burns TM; Nations S; Bril V; Wang AK; Elsheikh BH; Kissel JT; Saperstein D; Shaibani JA; Jackson C; Swenson A; Howard JF; Goyal N; David W; Wicklund M; Pulley M; Becker M; Mozaffar T; Benatar M; Pazcuzzi R; Simpson E; Rosenfeld J; Dimachkie MM; Statland JM; Barohn RJ;
    Neurology; 2016 Jul; 87(1):57-64. PubMed ID: 27306628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Randomized Open-Labeled Trial of Methotrexate as a Steroid-Sparing Agent for Patients With Generalized Myasthenia Gravis.
    Di L; Shen F; Wen X; Lu Y; Zhu W; Wang M; Da Y
    Front Immunol; 2022; 13():839075. PubMed ID: 35371086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.
    Oaklander AL; Lunn MP; Hughes RA; van Schaik IN; Frost C; Chalk CH
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD010369. PubMed ID: 28084646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corticosteroids for myasthenia gravis.
    Schneider-Gold C; Gajdos P; Toyka KV; Hohlfeld RR
    Cochrane Database Syst Rev; 2005 Apr; 2005(2):CD002828. PubMed ID: 15846640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-biologic, steroid-sparing therapies for non-infectious intermediate, posterior, and panuveitis in adults.
    Edwards Mayhew RG; Li T; McCann P; Leslie L; Strong Caldwell A; Palestine AG
    Cochrane Database Syst Rev; 2022 Oct; 10(10):CD014831. PubMed ID: 36315029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.
    Chande N; Townsend CM; Parker CE; MacDonald JK
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD000545. PubMed ID: 27783843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methotrexate for induction of remission in refractory Crohn's disease.
    McDonald JW; Wang Y; Tsoulis DJ; MacDonald JK; Feagan BG
    Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD003459. PubMed ID: 25099640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methotrexate for induction of remission in refractory Crohn's disease.
    McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
    Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.
    Chande N; Tsoulis DJ; MacDonald JK
    Cochrane Database Syst Rev; 2013 Apr; (4):CD000545. PubMed ID: 23633304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical and surgical treatment for ocular myasthenia.
    Benatar M; Kaminski H
    Cochrane Database Syst Rev; 2006 Apr; (2):CD005081. PubMed ID: 16625623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunosuppressive agents for myasthenia gravis.
    Hart IK; Sathasivam S; Sharshar T
    Cochrane Database Syst Rev; 2007 Oct; (4):CD005224. PubMed ID: 17943844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.
    Mahdi-Rogers M; Brassington R; Gunn AA; van Doorn PA; Hughes RA
    Cochrane Database Syst Rev; 2017 May; 5(5):CD003280. PubMed ID: 28481421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stopping oral steroid-sparing agents at initiation of rituximab in myasthenia gravis.
    Roda RH; Doherty L; Corse AM
    Neuromuscul Disord; 2019 Jul; 29(7):554-561. PubMed ID: 31296355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
    Benatar M; Kaminski HJ;
    Neurology; 2007 Jun; 68(24):2144-9. PubMed ID: 17460154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer occurrence following azathioprine treatment in myasthenia gravis patients: A systematic review and meta-analysis.
    Zhang Z; Wang M; Xu L; Jiang B; Jin T; Shi T; Xu B
    J Clin Neurosci; 2021 Jun; 88():70-74. PubMed ID: 33992207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease.
    Chande N; Patton PH; Tsoulis DJ; Thomas BS; MacDonald JK
    Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD000067. PubMed ID: 26517527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis.
    Bromberg MB; Wald JJ; Forshew DA; Feldman EL; Albers JW
    J Neurol Sci; 1997 Sep; 150(1):59-62. PubMed ID: 9260858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.